^
Association details:
| Biomarker: | HER-2 amplification + EGFR-ZNF880 fusion + EGFR E114K |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | lapatinib (EGFR inhibitor, HER2 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report
Published date:
12/18/2020
Excerpt:
We diagnosed her with metastatic breast cancer, positive for HER2....The results of circulating tumor DNA assays showed that other than HER2 amplification, novel EGFR-ZNF880 fusion and EGFR E114K mutations developed....This case report demonstrates that EGFR-ZNF880 fusion and EGFR E114K mutations may contribute or lead to the formation of a special HER2 dimer, which is rapidly resistant to lapatinib but sensitive to pyrotinib.
DOI:
10.1097/MD.0000000000023406
